Pegasus Laboratories/PRN Pharmacal has announced the addition of a new FDA conditionally approved drug, Felycin®-CA1 (sirolimus delayed-release tablets), to their portfolio. This first-in-class ...

Schrödinger, Inc. today announced encouraging initial clinical data from its ongoing Phase 1, open-label, dose-escalation study of SGR-1505 in patients with relapsed/refractory B-cell malignancies.